856677-05-9

Usage

Uses

Used in Medicinal Chemistry:
(5S)-N-[3-(4-Bromo-3-fluorophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide is used as a chemical intermediate for the synthesis of new pharmaceutical compounds. Its unique structural features, including the oxazolidinone ring, bromine and fluorine atoms, and the acetamide group, may contribute to the development of novel drugs with improved properties.
Used in Drug Development:
(5S)-N-[3-(4-Bromo-3-fluorophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide is used as a potential lead compound in drug discovery. Its structural features and potential biological activity make it a promising candidate for further optimization and development into therapeutic agents targeting various diseases and conditions.
Used in Pharmaceutical Industry:
(5S)-N-[3-(4-Bromo-3-fluorophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide is used as a building block for the design and synthesis of new pharmaceutical compounds. Its unique structural elements, such as the chiral center, bromine and fluorine atoms, and the acetamide group, can be exploited to create innovative drugs with enhanced efficacy, selectivity, and safety profiles.
Used in Research and Development:
(5S)-N-[3-(4-Bromo-3-fluorophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide is used as a research tool to study the structure-activity relationships of oxazolidinone derivatives and their potential applications in medicinal chemistry. Its unique features can provide valuable insights into the design and optimization of new drugs with improved pharmacological properties.

InChI:InChI=1/C12H12BrFN2O3/c1-7(17)15-5-9-6-16(12(18)19-9)8-2-3-10(13)11(14)4-8/h2-4,9H,5-6H2,1H3,(H,15,17)/t9-/m0/s1

Upstream product

• 1032827-78-3 (S)-2-((3-(4-bromo-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)isoindoline-1,3-dione 
• 396076-65-6 (4-bromo-3-fluoro-phenyl)-carbamic acid methyl ester 
• 183905-31-9 N-[(2S)-2-acetoxy-3-chloropropyl]acetamide 
• 1032827-77-2 2-((R)-3-(4-bromo-3-fluorophenylamino)-2-hydroxypropyl)isoindolin-1,3-dione 
• 856677-01-5 (R)-5-(azidomethyl)-3-(4-bromo-3-fluorophenyl)oxazolidin-2-one 
• 108-24-7 acetic anhydride 
• 856676-99-8 methanesulfonic acid (5R)-3-(4-bromo-3-fluorophenyl)-2-oxooxazolidin-5-ylmethyl ester 
• 444335-16-4 (R)-3-(4-bromo-3-fluorophenyl)-5-(hydroxylmethyl)oxazolidin-2-one 
• 510729-01-8 (4-bromo-3-fluorophenyl)carbamic acid benzyl ester 
• 656-65-5 3-fluoro-4-bromophenylamine 
• 75-36-5 acetyl chloride 
• 856677-03-7 (S)-5-(aminomethyl)-3-(4-bromo-3-fluorophenyl)oxazolidin-2-one 

Downstream Products

• 843647-60-9 (S)-N-[3-(2-fluoro-4'-formylbiphenyl-4-yl)-2-oxo-1,3-oxazolidine-5-ylmethyl]acetamide 
• 1032827-76-1 N-(((S)-3-(4-(4-ethoxycarbonylphenyl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 877875-99-5 (5S)-N-[3-(4'-cyano-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide 
• 1401341-59-0 C₂₁H₂₁FN₆O₄ 
• 1401341-60-3 C₂₀H₂₁FN₆O₃*ClH 
• 1401341-61-4 C₂₁H₂₃FN₆O₃ 
• 1401341-63-6 C₂₄H₂₇FN₆O₅ 
• 1401341-64-7 C₂₂H₂₅FN₆O₄ 
• 1401341-65-8 C₂₃H₂₅FN₆O₃ 
• 1401341-66-9 C₂₃H₂₃FN₆O₃ 
• 1401341-67-0 C₂₆H₃₁FN₆O₅ 
• 1401341-69-2 C₂₂H₂₃FN₆O₅ 
• 1401341-70-5 C₂₄H₂₅FN₆O₆ 
• 1401341-71-6 C₂₆H₂₇FN₆O₈ 

Relevant academic research and scientific papers

OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF

Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.

Design, synthesis and antibacterial evaluation of novel oxazolidinone derivatives nitrogen-containing fused heterocyclic moiety

A series of novel oxazolidinone derivatives with nitrogen-containing fused heterocyclic moiety were designed and synthesized in this article. Their antibacterial activities were measured against S. aureus, MRSA and MSSA by MIC assay. Most of them exhibite

Optimization of biaryloxazolidinone as promising antibacterial agents against antibiotic-susceptible and antibiotic-resistant gram-positive bacteria

We previously discovered a series of novel biaryloxazolidinone analogues bearing a hydrazone moiety with potent antibacterial activity. However, the most potent compound OB-104 exhibited undesirable chemical and metabolic instability. Herein, novel biaryloxazolidinone analogues were designed and synthesized to improve the chemical and metabolic stability. Compounds 6a-1, 6a-3, 14a-1, 14a-3 and 14a-7 showed significant antibacterial activity against the tested Gram-positive bacteria as compared to radezolid and linezolid. Further studies indicated that most of them exhibited improved water solubility and chemical stability. Compound 14a-7 had MIC values of 0.125–0.25 μg/mL against all tested Gram-positive bacteria, and showed excellent antibacterial activity against clinical isolates of antibiotic-susceptible and antibiotic-resistant bacteria. Moreover, it was stable in human liver microsome. From a safety viewpoint, it showed non-cytotoxic activity against hepatic cell and exhibited lower inhibitory activity against human MAO-A compared to linezolid. The potent antibacterial activity and all these improved drug-likeness properties and safety profile suggested that compound 14a-7 might be a promising drug candidate for further investigation.

Oxazolidinone-quinolone hybrid antibiotics

The present invention relates to compounds of the Formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:

NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME

Disclosed is a novel oxazolidinone derivative represented by Formula 1 above, in particular, a novel oxazolidinone compound having a cyclic amidoxime or cyclic amidrazone group. In Formula 1, R and Q are the same as defined in the detailed description. In addition, disclosed is a pharmaceutical composition for an antibiotic which includes the novel oxazolidinone derivative of Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The novel oxazolidinone derivative, the prodrug thereof, the hydrate thereof, the solvate thereof, the isomer thereof, and the pharmaceutically acceptable salt thereof have broad antibacterial spectrum against resistant bacteria, low toxicity and strong antibacterial effects against Gram-positive and Gram-negative bacteria and thus may be effectively used as antibiotics.

NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME

Disclosed is a novel oxazolidinone derivative represented by Formula 1 above, in particular, a novel oxazolidinone compound having a cyclic amidoxime or cyclic amidrazone group. In Formula 1, R and Q are the same as defined in the detailed description. In addition, disclosed is a pharmaceutical composition for an antibiotic which includes the novel oxazolidinone derivative of Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The novel oxazolidinone derivative, the prodrug thereof, the hydrate thereof, the solvate thereof, the isomer thereof, and the pharmaceutically acceptable salt thereof have broad antibacterial spectrum against resistant bacteria, low toxicity and strong antibacterial effects against Gram-positive and Gram-negative bacteria and thus may be effectively used as antibiotics.

NOVEL OXAZOLIDINONE DERIVATIVES, PROCESS FOR PREPARING THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

The present invention relates to a novel oxazolidinone derivative, its prodrugs, hydrates, solvates, isomers, pharmaceutically permitted salts, and its preparation methods and pharmaceutical compositions containing the same. The oxazolidinone derivative and its pharmaceutically permitted salts according to the present invention have wide antimicrobial spectrum against resistant bacteria and low toxicity, and they show strong antibacterial effect against gram-positive and gram-negative pathogens. So, they can be used as good antibiotics.